Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).
07-10-2019 | Prostate cancer | Video | Article
Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).